US 12,312,411 B2
Anti-CD38 binding domains
Kathleen Ann Elias, San Francisco, CA (US); Gregory Landes, San Bruno, CA (US); Shweta Singh, South San Francisco, CA (US); Wouter Korver, South San Francisco, CA (US); Andrew Walling Drake, South San Francisco, CA (US); Mary Haak-Frendscho, San Francisco, CA (US); Vinay Bhaskar, San Francisco, CA (US); and Erin Willert, Round Rock, TX (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jul. 1, 2022, as Appl. No. 17/810,377.
Application 17/810,377 is a continuation of application No. 16/751,107, filed on Jan. 23, 2020, granted, now 11,414,496.
Claims priority of provisional application 62/795,855, filed on Jan. 23, 2019.
Prior Publication US 2023/0203186 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2896 (2013.01) [C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. A composition comprising an anti-CD38-antigen binding domain that comprises a variable heavy domain (VH) comprising the sequence of SEQ ID NO: 9 and a variable light domain (VL) comprising the sequence of SEQ ID NO:13.